Multiple oncology immunotherapy programs report critical trial updates. IO Biotech's phase 3 trial for the off-the-shelf cancer vaccine Cylembio narrowly missed its primary endpoint when combined with Merck’s Keytruda in melanoma treatment, though subgroup analyses showed promising trends. Novartis's antibody ianalumab succeeded in two phase 3 trials targeting Sjögren’s disease and immune thrombocytopenia, promising new treatments for autoimmune disorders. Pfizer’s Padcev antibody-drug conjugate combined with Keytruda improved survival in bladder cancer in early analyses, opening potential new therapeutic avenues.